Press Releases

July 8, 2019
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting
NEW YORK , July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting, highlights recent clinical and regulatory
Additional Formats
June 17, 2019
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
NEW YORK , June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics announced today that ELZONRIS (tagraxofusp) was the subject of preclinical data in
Additional Formats
Displaying 1 - 10 of 19